Sen. Elizabeth Warren (Michael Brochstein/Sipa USA)(Sipa via AP Images)

De­moc­rats urge HHS to 'march-in' or en­able 'gov­ern­ment-use' rights to make Xtan­di less ex­pen­sive

HHS should move for­ward with a re­cent pe­ti­tion to al­low the gov­ern­ment to ex­er­cise its “march-in” rights to low­er the price of Astel­las and Pfiz­er’s can­cer drug Xtan­di, known gener­i­cal­ly as en­za­lu­tamide, Sens. Eliz­a­beth War­ren (D-MA) and An­gus King (I-ME), and Rep. Lloyd Doggett (D-TX) said in a let­ter to HHS Sec­re­tary Xavier Be­cer­ra late last week.

If NIH con­tin­ues to de­cide to nev­er use its march-in rights un­der the Bayh-Dole Act, the De­moc­rats note that the fed­er­al gov­ern­ment can al­so ex­er­cise its gov­ern­ment-use rights to per­mit gener­ic com­pe­ti­tion with Xtan­di.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.